Before the pandemic, pharmacy vaccinations were niche. Then COVID hit, and suddenly everyone got their shots at CVS or Walgreens. That habit stuck. The retail pharmacy market trends show that immunisations are now a major service line, generating billions in additional revenue. Flu, pneumonia, shingles, HPV — you name it.

Why is this a big deal? It expands the pharmacy's role from dispenser to primary care provider. States are expanding scope‑of‑practice laws, allowing pharmacists to prescribe birth control, naloxone, and even HIV prevention (PrEP). The retail pharmacy market research study notes that these clinical services have higher margins than product sales, and they build customer loyalty.

Challenges include reimbursement (not all insurers pay for pharmacist services) and training. But chains are investing heavily in certification programs. The result? Your local pharmacist might soon manage your blood pressure meds and give you a physical — all while you pick up your deodorant.

The future of retail pharmacy is clinical. And that's good for patients, payers, and the bottom line.